CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?

被引：0
|
作者：
Sakach, Elizabeth [1 ]
Keskinkilic, Merve [2 ]
Wood, Sarah [1 ]
Canning, Madison [1 ]
Kalinsky, Kevin [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Dokuz Eylul Univ, Dept Med Oncol, Fac Med, Izmir, Turkiye
来源：
CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2023年 / 24卷 / 09期
关键词：
CDK4/6; inhibitor; Hormone therapy; Metastatic breast cancer; Endocrine resistance; ctDNA; ADVANCED BREAST-CANCER; RIBOCICLIB PLUS FULVESTRANT; DOUBLE-BLIND; RESISTANCE; THERAPY; PALBOCICLIB; WOMEN; TRIAL; MULTICENTER; PROGRESSION;
D O I：
10.1007/s11864-023-01109-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER-2-) metastatic breast cancer (MBC) is the most common subtype of breast cancer. Due to therapeutic advances with molecularly targeted therapies, the prognosis for patients with metastatic disease has improved significantly. The advent of CDK4/6 inhibitors (CDK4/6i) has changed the treatment paradigm for patients with HR+HER2-MBC. CDK4/ 6i allowed for marked improvement in overall survival, delaying the time to chemotherapy initiation, and improved quality of life for our patients. Efforts are now focused on the best approach(es) for patients after progression on CDK4/6i. Can we further harness the benefit of CDK4/6i in novel combinations at the time of progression? Should we continue CDK4/6i or proceed other novel agents or endocrine therapies? As we advance our treatment strategies for HR+HER2-MBC, there is no longer a one-size-fits-all model, but instead a multifaceted and personalized approach lending to improved outcomes for our patients.
引用
收藏
页码：1103 / 1119
页数：17
相关论文
共 50 条
  • [11] The Role of CDK4/6 Inhibition in Breast Cancer
    Murphy, Conleth G.
    Dickler, Maura N.
    ONCOLOGIST, 2015, 20 (05): : 483 - U49
  • [12] CDK4/6 inhibition in luminal breast cancer
    Gampenrieder S.P.
    Rinnerthaler G.
    Greil R.
    memo - Magazine of European Medical Oncology, 2016, 9 (2) : 76 - 81
  • [13] Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HRD/HER2L metastatic breast cancer?
    Giordano, A.
    Lin, N. U.
    Tolaney, M.
    Mayer, L.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 10 - 14
  • [14] Transcriptional profiling of CTCs in metastatic breast cancer patients in the course of CDK4/6 inhibition
    Kasimir-Bauer, Sabine
    Gruber, Charlotte
    Moukas, Stefanos
    Tewes, Mitra
    Kolberg, Hans-Christian
    Kimmig, Rainer
    Keup, Corinna
    CANCER RESEARCH, 2023, 83 (05)
  • [15] CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
    Teleanu, M-V.
    Heilig, C. E.
    Hamacher, R. W.
    Bauer, S.
    Mayer-Steinacker, R.
    Gaidzik, V. I.
    Horak, P.
    Lanz, L-M.
    Muskatewitz, T.
    Suesse, H.
    Freitag, A.
    von Hornung, M.
    Wacker, L.
    Von Kalle, C.
    Barth, T.
    Froehling, S.
    Schlenk, R. F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1228 - S1228
  • [16] CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
    Froehling, S.
    Barth, T. F.
    Groeschel, S.
    Folprecht, G.
    Richter, S.
    Mayer-Steinacker, R.
    Schultheiss, M.
    Moeller, P.
    Bauer, S.
    Siveke, J. T.
    Dettmer, S.
    Richter, D.
    Heining, C.
    Horak, P.
    Glimm, H.
    Jaeger, D.
    Von Kalle, C.
    Schlenk, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [17] CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT-PMO-1601)
    Schlenk, R.
    Barth, T.
    Groschel, S.
    Heilig, C.
    Folprecht, G.
    Richter, S.
    Mayer-Steinacker, R.
    Markus, S.
    Moller, P.
    Bauer, S.
    Siveke, J.
    Dettmer, S.
    Richter, D.
    Heining, C.
    Horak, P.
    Jager, D.
    Glimm, H.
    von Kalle, C.
    Frohling, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 156 - 156
  • [18] The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma
    Ray-Coquard, Isabelle
    Monk, Bradley J.
    Lorusso, Domenica
    Mahdi, Haider
    Upadhyay, Vivek
    Graul, Regina
    Husain, Amreen
    Mirza, Mansoor Raza
    Slomovitz, Brian
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (12) : 1943 - 1949
  • [19] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [20] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
12345